Should levodopa dose be reduced when switched to stalevo?
Identifieur interne : 000C72 ( Main/Exploration ); précédent : 000C71; suivant : 000C73Should levodopa dose be reduced when switched to stalevo?
Auteurs : G. Linazasoro [Espagne] ; J. Kulisevsky [Espagne] ; B. Hernández [Espagne]Source :
- European Journal of Neurology [ 1351-5101 ] ; 2008-03.
English descriptors
- KwdEn :
Abstract
The addition of entacapone to levodopa‐carbidopa (LC) or the switch from LC to a tablet containing levodopa–carbidopa–entacapone (LCE) improves the wearing‐off phenomenon, increases the ‘on’ time and decreases the ‘off’ time, but the appearance or exacerbation of dyskinesias is the more frequent side‐effect. Thus, a reduction of the total levodopa dosage would be recommended. However, this could result in a lack of efficacy against the wearing‐off. We report on the results of a clinical trial conducted to determine the best way in terms of efficacy, tolerability and safety of switching from LC to LCE in patients with Parkinson's disease (PD) and end of dose wearing‐off. 39 patients with PD and wearing‐off without or with mild dyskinesias were randomly assigned to either a group receiving the same LC dosage or to a group in which the total LC amount was reduced by 15–25%. Four weeks after the change, both groups showed an increase in daily ‘on’ time and a reduction in the daily time spent in ‘off’. Two patients in each group experienced an increase in basal dyskinesias. No differences in clinical assessment between groups were found. Tolerance was excellent. This study suggests that switching from LC to LCE in patients with mild‐to‐moderate wearing‐off can be done safely with or without reducing the total LD amount, but in the clinical setting it would be more practical to keep the dosage of LC unchanged unless severe dyskinesias are present.
Url:
DOI: 10.1111/j.1468-1331.2007.02047.x
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Should levodopa dose be reduced when switched to stalevo?</title><author><name sortKey="Linazasoro, G" sort="Linazasoro, G" uniqKey="Linazasoro G" first="G." last="Linazasoro">G. Linazasoro</name></author><author><name sortKey="Kulisevsky, J" sort="Kulisevsky, J" uniqKey="Kulisevsky J" first="J." last="Kulisevsky">J. Kulisevsky</name></author><author><name sortKey="Hernandez, B" sort="Hernandez, B" uniqKey="Hernandez B" first="B." last="Hernández">B. Hernández</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:E43F2624C11E3E2413255A0484A03DC57193D2C1</idno><date when="2008" year="2008">2008</date><idno type="doi">10.1111/j.1468-1331.2007.02047.x</idno><idno type="url">https://api.istex.fr/document/E43F2624C11E3E2413255A0484A03DC57193D2C1/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000933</idno><idno type="wicri:Area/Main/Curation">000811</idno><idno type="wicri:Area/Main/Exploration">000C72</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Should levodopa dose be reduced when switched to stalevo?</title><author><name sortKey="Linazasoro, G" sort="Linazasoro, G" uniqKey="Linazasoro G" first="G." last="Linazasoro">G. Linazasoro</name><affiliation wicri:level="1"><country xml:lang="fr">Espagne</country><wicri:regionArea>Centro Investigación Parkinson, Policlínica Gipuzkoa, San Sebastián</wicri:regionArea><wicri:noRegion>San Sebastián</wicri:noRegion></affiliation></author><author><name sortKey="Kulisevsky, J" sort="Kulisevsky, J" uniqKey="Kulisevsky J" first="J." last="Kulisevsky">J. Kulisevsky</name><affiliation wicri:level="3"><country xml:lang="fr">Espagne</country><wicri:regionArea>Servicio de Neurología, Hospital Santa Creu y Sant Pau, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Hernandez, B" sort="Hernandez, B" uniqKey="Hernandez B" first="B." last="Hernández">B. Hernández</name><affiliation wicri:level="3"><country xml:lang="fr">Espagne</country><wicri:regionArea>Medical Department, Novartis Pharmaceutica, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">European Journal of Neurology</title><idno type="ISSN">1351-5101</idno><idno type="eISSN">1468-1331</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2008-03">2008-03</date><biblScope unit="volume">15</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="257">257</biblScope><biblScope unit="page" to="261">261</biblScope></imprint><idno type="ISSN">1351-5101</idno></series><idno type="istex">E43F2624C11E3E2413255A0484A03DC57193D2C1</idno><idno type="DOI">10.1111/j.1468-1331.2007.02047.x</idno><idno type="ArticleID">ENE2047</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1351-5101</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>entacapone</term><term>levodopa</term><term>parkinson’s disease</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The addition of entacapone to levodopa‐carbidopa (LC) or the switch from LC to a tablet containing levodopa–carbidopa–entacapone (LCE) improves the wearing‐off phenomenon, increases the ‘on’ time and decreases the ‘off’ time, but the appearance or exacerbation of dyskinesias is the more frequent side‐effect. Thus, a reduction of the total levodopa dosage would be recommended. However, this could result in a lack of efficacy against the wearing‐off. We report on the results of a clinical trial conducted to determine the best way in terms of efficacy, tolerability and safety of switching from LC to LCE in patients with Parkinson's disease (PD) and end of dose wearing‐off. 39 patients with PD and wearing‐off without or with mild dyskinesias were randomly assigned to either a group receiving the same LC dosage or to a group in which the total LC amount was reduced by 15–25%. Four weeks after the change, both groups showed an increase in daily ‘on’ time and a reduction in the daily time spent in ‘off’. Two patients in each group experienced an increase in basal dyskinesias. No differences in clinical assessment between groups were found. Tolerance was excellent. This study suggests that switching from LC to LCE in patients with mild‐to‐moderate wearing‐off can be done safely with or without reducing the total LD amount, but in the clinical setting it would be more practical to keep the dosage of LC unchanged unless severe dyskinesias are present.</div></front></TEI><affiliations><list><country><li>Espagne</li></country><region><li>Catalogne</li></region><settlement><li>Barcelone</li></settlement></list><tree><country name="Espagne"><noRegion><name sortKey="Linazasoro, G" sort="Linazasoro, G" uniqKey="Linazasoro G" first="G." last="Linazasoro">G. Linazasoro</name></noRegion><name sortKey="Hernandez, B" sort="Hernandez, B" uniqKey="Hernandez B" first="B." last="Hernández">B. Hernández</name><name sortKey="Kulisevsky, J" sort="Kulisevsky, J" uniqKey="Kulisevsky J" first="J." last="Kulisevsky">J. Kulisevsky</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C72 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000C72 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:E43F2624C11E3E2413255A0484A03DC57193D2C1
|texte= Should levodopa dose be reduced when switched to stalevo?
}}
| This area was generated with Dilib version V0.6.23. |  |